Skip to main content
ADPT
NASDAQ Life Sciences

Adaptive Biotechnologies Finalizes $345M Convertible Notes Offering, Repays OrbiMed Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
9
Price
$17.37
Mkt Cap
$2.78B
52W Low
$9.955
52W High
$20.76
52W Position info
74% above low
Off High info
16% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ADPT sits 74% above its 52-week low of $9.955.

Summary

Adaptive Biotechnologies issued $345 million in convertible senior notes, using a significant portion to repay a $156.9 million revenue interest agreement and fund general corporate purposes, while also implementing capped call transactions to manage potential dilution.


Key Events · Financing and Capital Events · ADPT

  • Convertible Notes Issued

    The company issued $345 million aggregate principal amount of 0% Convertible Senior Notes due 2031, including the full exercise of the initial purchasers' $45 million option. Net proceeds were approximately $334.5 million.

  • OrbiMed Debt Repaid

    Used $156.9 million of the net proceeds to fully repay the OrbiMed Revenue Interest Purchase Agreement, which had a 156% return cap. This terminates a material definitive agreement and improves financial flexibility.

  • Dilution Mitigation via Capped Calls

    Entered into capped call transactions for $25.6 million, with a cap price of $34.44 per share (100% premium over the June 16, 2026 closing price of $17.22), designed to reduce potential stock dilution up to that price.

  • Concurrent Share Repurchase

    Repurchased 1,451,800 shares of common stock for $25.0 million concurrently with the offering, further mitigating immediate dilution.


Analysis · ADPT · Life Sciences

Adaptive Biotechnologies has completed a significant financing event by issuing $345 million in 0% convertible senior notes. The net proceeds of $334.5 million will be primarily used to repay a $156.9 million revenue interest agreement with OrbiMed, strengthening the company's balance sheet and improving financial flexibility. The offering was priced at a 40% premium to the stock's price on June 16, 2026, and includes capped call transactions to mitigate dilution up to a 100% premium. This capital raise provides substantial funds for general corporate purposes and strategic initiatives in the MRD business, following recent news of evaluating a separation of its immune medicine business.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADPT was trading at $17.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $9.96 to $20.76. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Nov 04, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.48
Real-time Price: $28.57 info
Change: +$0.085 (+0.30%) info
Market Cap: $4.636B info
ADPT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $28.80
Real-time Price: $28.57 info
Change: -$0.2349 (-0.82%) info
Market Cap: $4.636B info
ADPT
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $27.98
Real-time Price: $28.57 info
Change: +$0.585 (+2%) info
Market Cap: $4.636B info
ADPT
Aug 19, 2026, 8:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $28.57 info
Change: +$2.77 (+11%) info
Market Cap: $4.636B info
ADPT
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.66
Real-time Price: $28.57 info
Change: +$3.90 (+16%) info
Market Cap: $4.636B info